ClinicalTrials.gg
CompletedNCT05186051Updated Jul 11, 2022

A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZYIL1 in Subjects With Cryopyrin Associated Periodic Syndromes (CAPS)

A Phase 2 interventional study of ZYIL1 capsule in Cryopyrin Associated Periodic Syndrome, sponsored by Zydus Lifesciences Limited. Completed at 1 site in Australia. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-07-11.

Sponsored by Zydus Lifesciences Limited · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
3
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

ZYIL1 is expected to show benefit in patients with CAPS. The present study aims to determine the safety, tolerability, pharmacokinetics, and pharmacodynamics of ZYIL1 when administered to subjects with CAPS.

Read the detailed description

This is a phase 2a, prospective, open-label study. Primary objective of the study is to determine safety and tolerability profile of twice daily oral administration of ZYIL1 administered for 7 days. The study will be conducted in 3 subjects having CAPS as per eligibility criteria. The study will be divided in three periods: Screening Period; Run-in Period and Study Period.

02

Conditions studied

  • Cryopyrin Associated Periodic Syndrome

Keywords

  • NLRP3
  • NLPR3 Inflammasone inhibitor
03

In context

Cryopyrin-Associated Periodic Syndromes

35 studies on the registry are indexed under Cryopyrin-Associated Periodic Syndromes; 5 are open to participants now.

This study's enrollment of 3 is below the median of 19 across 27 interventional studies indexed under Cryopyrin-Associated Periodic Syndromes.

Browse Cryopyrin-Associated Periodic Syndromes studies →

Lead sponsor

Zydus Lifesciences Limited is the lead sponsor of 21 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects with a confirmed diagnosis of CAPS (FCAS, NOMID, or MWS) aged 18 to 75 years inclusive at screening A confirmed diagnosis of CAPS comprises the following:

    1. Subject has previously experienced at least 2 typical clinical symptoms of CAPS (may include urticarial skin rash, myalgia, arthralgia, recurrent fever, fatigue/malaise, headache, conjunctivitis, and any other autoinflammatory symptom); and
    2. Documented verification of a genetic mutation in NLRP3.
  2. Positive response of ZYIL1 in inhibiting secreted IL-1β from peripheral blood mononuclear cells isolated from the subject's blood treated with LPS ex vivo showing half maximal inhibitory concentration below 500 nM.
  3. Subject must be willing to discontinue current anti-IL-1 treatment prior to study drug dosing if applicable.
  4. Subject must demonstrate flaring of CAPS de novo or after discontinuation of anti-IL-1 inhibitor treatment. Flaring is defined as worsening of disease activity as per physician global assessment of disease activity with elevation of CRP (>2 x [ULN]).
  5. Subject must have a (BMI) between ≥18.0 and ≤38.0 kg/m2 at Screening.
  6. Female subject of reproductive age must be non-pregnant and non-lactating, and must use an acceptable, highly effective from screening until 1 month after the last dose of study drug.
  7. Male subject must be willing to use contraception and must not donate sperm for at least 90 days after the last dose of study drug.

Exclusion criteria

Exclusion Criteria:

  1. Any severe, progressive, or uncontrolled medical condition within the past 3 months that might have impact on the clinical trial as per the investigator's discretion.
  2. Use of any drug or investigational medical device or participation in other clinical study within 4 weeks prior to Screening or 5 half- lives of the product (whichever is longer).
  3. Any laboratory or findings during the screening in the opinion of the Investigator.
  4. Estimated (eGFR) \< 90 mL/min/1.73m2, as measured by the equation at screening
  5. Total above (ULN) or (SGOT)/ALT(SGPT) > 1.5 times of ULN at screening
  6. corrected for heart rate using Fridericia's method (QTcF) > 450 msec at screening
  7. History of clinically significant , intolerance, or allergies, as determined by the investigator.
  8. History of fever, cough or any other active systemic infections within 2 weeks prior to receiving study drug.
  9. History or presence of alcohol abuse (alcohol consumption more than 40 g/4 units/4standard drinks per day), or drug habituation, or any prior intravenous usage of an illicit substance
  10. Surgery within last 3 months or planned major surgery within next 3 months from the date of screening (other than minor cosmetic surgery and minor dental surgery).
  11. Subjects who have donated one unit (490 mL) of blood in the past 3 months.
  12. Use or intend to use any medications/products known to alter drug absorption, metabolism, or elimination processes including St John's Wort within 4 weeks prior to receiving study drug and up to end of study. Use of such medication will be considered on a case-by-case basis as per the opinion of the investigator and/or independent medical monitor, or use of grapefruit or similar substances (Seville oranges or marmalade, grapefruit juice, grapefruit hybrids, pomelos, exotic citrus fruits or fruit juices) within 7 days prior to the Run-in period.
  13. Use or intend to use any over-the-counter (vitamins, minerals, and phytotherapeutic/herbal/plant-derived preparations) or prescription medications within 7 days or 5 half-lives (whichever is longer) prior to receiving study drug, with the exception of hormone replacement therapy and therapies for chronic stable diseases that have been stable for at least 30 days prior to screening and until Day 1, unless deemed acceptable by the investigator
  14. History of or positive screening test for infection (defined as positive for hepatitis C virus antibody), infection (defined as positive for hepatitis B surface antigen), or I or II.
  15. Female subjects who are pregnant, currently breastfeeding, or attempting to conceive.
  16. Any disorder that, in the Investigator's opinion, may interfere with study compliance, such as significant mental, nervous disorder or other illness. In making this assessment, the Investigator must refer to the study information provided including the Investigator's Brochure.
  17. Inability to be venipuncture or tolerate venous puncture.
  18. Any condition or abnormal baseline findings that in investigator's judgment might increase the risk to the subject or decrease the chance of obtaining satisfactory data needed to obtain the objective of the study.
  19. Other unspecified reasons that, in the opinion of the investigator make the subject unsuitable for the study.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
3 participants (actual)

Study arms

  • Experimental
    ZYIL1 Capsule

    subject will receive 50 mg twice daily (BD) dose for 7 days

    Drug: ZYIL1 capsule

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence and Severity of Adverse event of ZYIL1

    The Common Terminology Criteria for Adverse Event (CTCAE) (Version 5.0 or higher) system will be used for reporting and grading

    Time frame: Baseline to Day 7

Secondary outcomes

  1. Maximum concentration (Cmax)

    Blood samples will be withdrawn on Day 1 and Day 7 to evaluate maximum concentration

    Time frame: Pre-dose to Day 7

  2. To evaluate disease activity scores based on 5 point physician and patient global assessment over 7 days treatment of ZYIL1

    Physician global assessment on 5 point scale score will be taken

    Time frame: Baseline to Day 10

  3. Time to reach maximum concentration (Tmax)

    Blood samples will be withdrawn on Day 1 and Day 7 to evaluate Time to reach maximum concentration

    Time frame: Pre-dose to Day 7

  4. Area under the curve for dosing interval(12 hours) AUCtau

    Blood samples will be withdrawn on Day 1 and Day 7 to evaluate AUCtau

    Time frame: Pre-dose to Day 7

  5. Change in WBC count

    Blood samples will be collected from pre-dose till Day 10 to evaluate the change

    Time frame: Baseline to Day 10

  6. Change in IL-1β

    Blood samples will be collected from pre-dose till Day 10 to evaluate the change

    Time frame: Baseline to Day 10

  7. Change in Serum amyloid protein A

    Blood samples will be collected from pre-dose till Day 10 to evaluate the change

    Time frame: Baseline to Day 10

  8. Change in IL-6

    Blood samples will be collected from pre-dose till Day 10 to evaluate the change

    Time frame: Baseline to Day 10

  9. Change in CRP

    Blood samples will be collected from pre-dose till Day 10 to evaluate the change

    Time frame: Baseline to Day 10

07

Study locations

1 site
  • Department of Clinical Immunology and Allergy
    Adelaide, 5000, Australia
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2022 to primary completion in Jul 2022, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 23, 2021
First posted
Jan 11, 2022
StartActual
Jun 1, 2022
Primary completionActual
Jul 2, 2022
CompletionActual
Jul 2, 2022
Last update
Jul 11, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 11, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05186051
Responsible party
Sponsor
First posted
Jan 11, 2022
Start date
Jun 1, 2022
Primary completion
Jul 2, 2022
Completion
Jul 2, 2022
Last update
Jul 11, 2022

Study contacts

Dr Deven Parmar, MD
study director · Cadila Healthcare Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ZYIL1

Start the discussion